Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease (Syn-T)

November 6, 2026 updated by: CND Life Sciences

Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies.

Primary Objectives

  1. Identify which ET patients have P-SYN pathology indicative of prodromal PD
  2. Predict which patients are most likely to phenoconvert to PD

Study Overview

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Arizona
      • Scottsdale, Arizona, United States, 85258
        • Recruiting
        • Movement Disorders Center of Arizona
        • Contact:
        • Principal Investigator:
          • Virgilio Gerald H Evidente, MD
      • Scottsdale, Arizona, United States, 85258
        • Recruiting
        • CND Clinical Research Center
        • Contact:
        • Principal Investigator:
          • Padma Mahant, MD
    • California
      • Irvine, California, United States, 92617
        • Not yet recruiting
        • University of California Irvine Health
        • Contact:
        • Principal Investigator:
          • Ann Ly, MD
        • Sub-Investigator:
          • Niki Maki, MD
      • Los Angeles, California, United States, 90048
        • Not yet recruiting
        • Cedars-Sinai Medical Center
        • Principal Investigator:
          • Michele Tagliati, MD
        • Contact:
        • Contact:
    • Florida
      • Orlando, Florida, United States, 32825
        • Recruiting
        • Neurology One
        • Principal Investigator:
          • Ramon L Rodriguez, MD, FAAN
        • Contact:
        • Contact:
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Recruiting
        • University of Kansas Medical Center
        • Sub-Investigator:
          • Kelly Lyons, PhD
        • Contact:
          • Kim Lee, Clinical Research Coordinator
          • Phone Number: 913-588-0013
          • Email: klee9@kumc.edu
        • Principal Investigator:
          • Angela Richmond, MD
    • Kentucky
      • Louisville, Kentucky, United States, 40202
    • Michigan
      • Farmington Hills, Michigan, United States, 48334
        • Recruiting
        • Quest Research Institute
        • Contact:
        • Principal Investigator:
          • Aaron Ellenbogen, DO
    • Tennessee
      • Memphis, Tennessee, United States, 38157
        • Recruiting
        • Veracity Neurosciences LLC
        • Contact:
        • Principal Investigator:
          • Mark LeDoux, MD, PhD
      • Nashville, Tennessee, United States, 37232
        • Not yet recruiting
        • Vanderbilt University Medical Center
        • Contact:
        • Contact:
        • Principal Investigator:
          • Cherrie Yu, MD
        • Sub-Investigator:
          • Amanda Currie, MD
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • Baylor College of Medicine
        • Contact:
        • Contact:
        • Principal Investigator:
          • Steven Bellows, MD
        • Sub-Investigator:
          • Karim Makhoul, MD
        • Sub-Investigator:
          • Yutong Taneff, NP

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Subjects will be enrolled from up to 18 sites across the US from academic institutions and private clinics.

Description

Inclusion Criteria:

  • Age 50-85 years old
  • Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR
  • Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."
  • Willing to participate in all study procedures
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Under age 50, Over age 85
  • Clinical evidence of severe peripheral vascular disease
  • Clinically active coronary artery or cerebrovascular disease
  • Participant is currently on anticoagulant or dual anti-platelet therapy
  • Alcoholism
  • Allergic reaction to local anesthesia
  • History of or increased risk for impaired wound healing, scarring, or keloid formation
  • Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise
  • History of other neurodegenerative disorder or evidence of neurological co-pathology
  • Abnormal DaTscan
  • Participant is currently receiving treatment with carbidopa-levodopa for PD
  • Isolated focal tremors (head, voice)
  • Task-specific tremor (e.g., primary writing tremor)
  • Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET
  • Sudden onset and step-wise deterioration
  • Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Essential Tremor

Those diagnosed with Essential Tremor

Essential Tremor Plus

Those diagnosed with Essential Tremor Plus

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantity of P-SYN in skin
Time Frame: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24

Quantity of P-SYN in biopsies as a biomarker for disease progression

From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
Rate of Phenoconversion
Time Frame: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24

Rate of phenoconversion from Essential Tremor to Parkinson's Disease over 24 months

From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 18, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2029

Study Registration Dates

First Submitted

February 13, 2026

First Submitted That Met QC Criteria

February 19, 2026

First Posted (Actual)

February 23, 2026

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CND-106
  • R44NS143486-01 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe